What Biogen (BIIB)'s 52-Week Litifilimab CLE Data Means For Shareholders

Biogen Inc. recently reported 52-week Phase 2 results from the AMETHYST study of litifilimab in cutaneous lupus erythematosus, showing sustained improvements in skin disease activity and a generally well tolerated safety profile in patients who had not responded to or tolerated standard antimalarial therapies. The extended data, supported by the FDA’s Breakthrough Therapy Designation for litifilimab in CLE, reinforce its potential as a first-in-class, once-monthly therapy targeting BDCA2 on...